Press Releases

Parkin tumor suppressor blocks tumor growth and invasion by inhibiting metabolic reprogramming and mitochondrial function.

The collaboratory led by Wistar investigators will continue to test novel combined immunotherapies to advance research towards a cure for HIV.

PHILADELPHIA — (July 30, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Daniel Claiborne, Ph.D., as Caspar Wistar Fellow in the Vaccine & Immunotherapy Center (VIC).

Through alternative polyadenylation, RNA molecules are directed to sites of protein synthesis to facilitate production of certain proteins where they are most needed.

The newly identified sugar and metabolic signatures may help predict duration and probability of HIV remission after antiretroviral therapy interruption during cure-directed clinical trials.